Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Novacyt Yönetim

Yönetim kriter kontrolleri 1/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Lyn Rees

İcra Kurulu Başkanı

UK£336.1k

Toplam tazminat

CEO maaş yüzdesi	31.0%
CEO görev süresi	less than a year
CEO sahipliği	n/a
Yönetim ortalama görev süresi	less than a year
Yönetim Kurulu ortalama görev süresi	1.1yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Lyn Rees'un ücretlendirmesi Novacyt'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-UK£37m
Mar 31 2024	n/a	n/a	-UK£33m
Dec 31 2023	UK£336k	UK£104k	-UK£28m

Tazminat ve Piyasa: Lyn 'ın toplam tazminatı ($USD 446.36K ) German pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 503.65K ).

Tazminat ve Kazançlar: Lyn şirketinin tazminatını şirket performansıyla karşılaştırmak için yeterli veri yok.

CEO

Lyn Rees (51 yo)

less than a year

Görev süresi

UK£336,106

Tazminat

Mr. Lyn Dafydd Rees serves as Executive Director at Novacyt S. A. since September 2023 and serves as its Chief Executive Officer since May 01, 2024. He serves as Non-Executive Director at MyHealthChecked P...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Lyn Rees	CEO & Executive Director	less than a year	UK£336.11k	Veri yok
Steve Gibson	CFO & Director	less than a year	Veri yok	Veri yok
Bryan Close	Chief Operations Officer	2.8yrs	Veri yok	Veri yok
Joanne Mason	Chief Scientific Officer & Director	less than a year	Veri yok	Veri yok
David Franks	Chief Human Resources Officer	3.5yrs	Veri yok	Veri yok
Paul Oladimeji	Group Head of R&D	no data	Veri yok	Veri yok

0.8yrs

Ortalama Görev Süresi

Deneyimli Yönetim: NYZ 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 0.8 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Lyn Rees	CEO & Executive Director	1.1yrs	UK£336.11k	Veri yok
Steve Gibson	CFO & Director	less than a year	Veri yok	Veri yok
Joanne Mason	Chief Scientific Officer & Director	less than a year	Veri yok	Veri yok
John Brown	Non-Executive Chairman	1.1yrs	UK£15.24k	Veri yok
Juliet Thompson	Independent Non-Executive Director	7.3yrs	UK£48.93k	Veri yok
Jean-Pierre Crinelli	Independent Non-Executive Director	no data	UK£34.04k	0.048% € 22.3k
David Gardner	Member of Scientific Committee	no data	Veri yok	Veri yok
Marco Zonta	Member of Scientific Committee	no data	Veri yok	Veri yok
Isabelle Cartier	Member of Scientific Committee	no data	Veri yok	Veri yok
Geneviève Bourg-Heckly	Member of Scientific Committee	no data	Veri yok	Veri yok

1.1yrs

Ortalama Görev Süresi

54.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: NYZ 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 1.1 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Novacyt Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Novacyt S.A. Appoints John Brown Cbe as Chairman, Effective from 1 October 2024

Novacyt S.A., Annual General Meeting, Jun 26, 2024

Less than half of directors are independent

Novacyt S.A. Announces Changes to Its Board, Effective on May 1, 2024

Novacyt S.A., Annual General Meeting, Jun 15, 2023

Novacyt S.A. Announces Retirement of Non-Executive Director, Effective on 31 December 2022

Recent updates

Novacyt S.A. Closure of IT-IS International Limited

First half 2024 earnings released: UK£0.25 loss per share (vs UK£0.12 loss in 1H 2023)

Novacyt S.A. Appoints John Brown Cbe as Chairman, Effective from 1 October 2024

New minor risk - Financial data availability

Novacyt S.A. to Report First Half, 2024 Results on Sep 26, 2024

Novacyt S.A., Annual General Meeting, Jun 26, 2024

Novacyt S.A. to Report Fiscal Year 2023 Results on May 30, 2024

Less than half of directors are independent

Novacyt S.A. Notes DHSC Application for Summary Judgment Dismissed

New minor risk - Financial data availability

Novacyt S.A. Announces Changes to Its Board, Effective on May 1, 2024

First half 2023 earnings released: UK£0.12 loss per share (vs UK£0.071 loss in 1H 2022)

New major risk - Revenue and earnings growth

Novacyt S.A. to Report Q2, 2023 Results on Sep 28, 2023

Novacyt S.A. Provides Group Revenue Guidance for the First Half Ended June 30, 2023

New major risk - Share price stability

Novacyt S.A., Annual General Meeting, Jun 15, 2023

Full year 2022 earnings released: UK£0.31 loss per share (vs UK£0.14 loss in FY 2021)

Now 23% undervalued after recent price drop

Novacyt S.A. to Report Fiscal Year 2022 Results on Apr 24, 2023

Now 21% undervalued after recent price drop

Novacyt S.A. Announces Retirement of Non-Executive Director, Effective on 31 December 2022

Novacyt Announces Step Down of David Allmond as Member of the Board

Novacyt Announces Approval of genesig® SARS-CoV-2 Winterplex® 3 Gene Assay Panel in the UK Under CTDA Legislation

Now 24% undervalued after recent price drop

First half 2022 earnings released: UK£0.07 loss per share (vs UK£0.18 loss in 1H 2021)

Novacyt S.A. Provides Group Financial Guidance for the Third Quarter and Year-To-Date Ended September 2022 and Fourth Quarter of 2022

Novacyt S.A. to Report First Half, 2022 Results on Sep 29, 2022

Novacyt Announces the Launch of the First Fully Lyophilised (Freeze-Dried), Direct-To-PCR Assays

Novacyt S.A. Launches Research-Use-Only Adenovirus F41 Assay

Novacyt S.A. Announces Approval of exsig COVID-19 Direct test in the UK

Novacyt Announces the Launch of Its Research-Use-Only Polymerase Chain Reaction Monkeypox Assay in Response to the Recent Outbreak of the Virus in Non-Endemic Countries

Novacyt S.A., Annual General Meeting, Jun 21, 2022

Full year 2021 earnings released: UK£0.14 loss per share (vs UK£1.94 profit in FY 2020)

Novacyt S.A. Provides Update on DHSC Dispute

Novacyt Announces Approval of COVID-19 Test Under CTDA Legislation

CEO & Director recently bought €121k worth of stock

Novacyt S.A. Announces Approval of the First Direct-To-PCR Covid-19 Test in the UK Under CTDA Legislation

Novacyt S.A. to Report Fiscal Year 2021 Results on Apr 25, 2022

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Novacyt S.A. Reiterate Revenue Guidance for the Full Year

Full year 2020 earnings released: EPS UK£1.94 (vs UK£0.072 loss in FY 2019)

Novacyt S.A. Provides Sales Guidance for the Full Year 2021

Novacyt S.A. Announces the Launch of Two New Polymerase Chain Reaction Assays, Expanding its genesig® COVID-19 and SNPsig® SARS-CoV-2 Variant Detection Portfolios

Novacyt S.A. Announces Launch of VersaLab™ Portable

Investor sentiment deteriorated over the past week

Novacyt S.A. Announces Inclusion of SNPsig SARS-CoV-2 PCR Genotyping Portfolio in the NHS England Framework and Expansion of SNPsig Product Range

Investor sentiment improved over the past week

Novacyt S.A. Provides Earnings Guidance for the Year 2021

Investor sentiment deteriorated over the past week

New 90-day low: €7.80

Novacyt S.A. Announces Launch of PCR Genotyping Assay Portfolio to Detect Covid-19 Variants

Investor sentiment deteriorated over the past week

New 90-day high: €13.26

Investor sentiment improved over the past week

Novacyt S.A. Announces Board Changes

Novacyt S.A. Appoints James McCarthy as Chief Financial Officer

Novacyt S.A. Announces the Development of Three Tests for New Strains of COVID-19 and Avian Influenza

Market bids up stock over the past week

Market bids up stock over the past week

CEO & Director recently bought €558k worth of stock

Market pulls back on stock over the past week

Market bids up stock over the past week

Market pulls back on stock over the past week

Market bids up stock over the past week